| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于治疗前列腺癌的组合物和疫苗 | CN201480046124.1 | 2014-08-21 | CN105517566A | 2016-04-20 | 卡尔-约瑟夫·卡伦; 马里奥拉·福廷-姆莱泽科; 乌尔丽克·格纳德-福格特; 托马斯·兰德尔 |
| 本发明涉及组合物，所述组合物包含至少一种编码能够在哺乳动物中诱发(适应性)免疫反应的抗原的组合的mRNA，其中所述抗原选自由以下组成的组：PSA(前列腺特异性抗原)、PSMA(前列腺特异性膜抗原)、PSCA(前列腺干细胞抗原)、STEAP(前列腺的六跨膜上皮抗原)、MUC1(黏蛋白1)和PAP(前列腺酸性磷酸酶)。本发明还涉及疫苗，所述疫苗包含至少一种编码此种抗原组合的mRNA，并且涉及所述组合物(用于制备疫苗)和/或所述疫苗用于诱发(适应性)免疫反应以用于治疗前列腺癌(PCa)，优选地前列腺腺癌，局部限制性前列腺癌，局部晚期前列腺癌，转移的前列腺癌，去势抵抗性(激素难治性)前列腺癌，转移的去势抵抗性前列腺癌和非转移的去势抵抗性前列腺癌，和与其相关的疾病或病症的用途。最后，本发明涉及试剂盒，尤其是具有多个部分的试剂盒，其包含所述组合物和/或所述疫苗。 | ||||||
| 2 | 包含融合蛋白的癌症治疗用药物组合物 | CN201380019776.1 | 2013-02-15 | CN104220085A | 2014-12-17 | 渡部昌实; 公文裕巳; 那须保友 |
| 本发明的目的在于将癌特异性抗原与细胞因子的融合蛋白用作癌症的预防剂或治疗剂。一种癌的预防或治疗用药物组合物，其包含癌特异性抗原与选自由人IL2(hIL2)、人IL4(hIL4)、人IL7(hIL7)、人GMCSF(hGMCSF)、小鼠IL4(mIL4)和小鼠GMCSF(mGMCSF)组成的组中的细胞因子的融合蛋白作为有效成分。 | ||||||
| 3 | 分析装置 | CN201480074474.9 | 2014-05-19 | CN105940306A | 2016-09-14 | 滨田和幸; 秋场猛; 大山力; 米山徹; 飞泽悠葵; 竹内俊文 |
| 一种自动分析装置(10)设有：尖端架(11)，储存移液管尖端；移液管(12)，样本被注入到其中；搬运单元(13)，平移地搬运移液管(12)；试剂架(14)；反应单元(15)；检测单元(16)；以及检测模块单元(17)。尖端架(11)储存的移液管尖端具有对样本进行直接光学检测的平面结构。尖端架(11)在接纳移液管尖端的孔中包括与移液管尖端的结构相对应的导向件。泵的驱动使得样本经由安装于移液管(12)的末端的移液管尖端而注入或排出移液管(12)。在检测单元(16)中，借助移液管尖端执行测量，移液管尖端被设置为使得接收光的平面垂直于光轴。 | ||||||
| 4 | 共有前列腺抗原、编码所述抗原的核酸分子以及包含所述核酸分子的疫苗及其用途 | CN201180064660.0 | 2011-11-14 | CN103314002B | 2016-09-07 | D·B·韦纳; 严健; B·费拉罗; N·Y·萨德赛; M·P·拉马纳坦 |
| 本文中提供了能够在被靶向的物种中打断耐受性的前列腺抗原的共有氨基酸序列，包括PSA、PSMA、STEAP和PSCA抗原。还提供了编码前列腺抗原PSA、PSMA、STEAP和PSCA的一种或多种共有氨基酸序列的核酸序列以及表达所述序列的基因构建体/载体和疫苗。本文中还提供了通过施用提供的疫苗、蛋白质和/或核酸序列的一种或多种产生针对前列腺癌细胞的自身免疫反应的方法。 | ||||||
| 5 | 共有前列腺抗原、编码所述抗原的核酸分子以及包含所述核酸分子的疫苗及其用途 | CN201180064660.0 | 2011-11-14 | CN103314002A | 2013-09-18 | D·B·韦纳; 严健; B·费拉罗; N·Y·萨德赛; M·P·拉马纳坦 |
| 本发明中提供了能够在被靶向的物种中打断耐受性的前列腺抗原的共有氨基酸序列，包括PSA、PSMA、STEAP和PSCA抗原。还提供了编码前列腺抗原PSA、PSMA、STEAP和PSCA的一种或多种共有氨基酸序列的核酸序列以及表达所述序列的基因构建体/载体和疫苗。本发明中还提供了通过施用提供的疫苗、蛋白质和/或核酸序列的一种或多种产生针对前列腺癌细胞的自身免疫反应的方法。 | ||||||
| 6 | MANUFACTURING DEVICE AND METHOD OF AN IMMUNOTHERAPEUTIC FORMULATION COMPRISING A RECOMBINANT LISTERIA STRAIN | US15777480 | 2016-11-18 | US20180325964A1 | 2018-11-15 | Anil Eapen; Robert Petit |
| Provided herein are an apparatus and process for manufacturing a formulation comprising a drug substance, said drug substance comprising a recombinant Listeria strain comprising a prostate specific antigen (PSA) or a chimeric HER2 antigen fused to a Listeriolysin O (LLO) protein fragment. | ||||||
| 7 | Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment | US15563447 | 2016-09-14 | US20180305702A1 | 2018-10-25 | Robert Petit; Michael F. Princiotta; Kyle Perry |
| Disclosed herein are recombinant Listeria strains comprising nucleotides encoding two or more heterologous antigens each fused to a truncated LLO, an N-terminal ActA or a PEST-sequence, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same. | ||||||
| 8 | Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same | US15207271 | 2016-07-11 | US09913885B2 | 2018-03-13 | David Weiner; Jian Yan; Bernadette Ferraro; Niranjan Y. Sardesai; Mathura P. Ramanathan |
| Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | ||||||
| 9 | Fluidic systems and methods for analyses | US15196922 | 2016-06-29 | US09827563B2 | 2017-11-28 | David Steinmiller; Vincent Linder |
| Fluidic systems and methods for analyses are provided. In some embodiments, systems and methods for improved measurement of absorbance/transmission through fluidic systems are described. Specifically, in one set of embodiments, optical elements are fabricated on one side of a transparent fluidic device opposite a series of fluidic channels. The optical elements may guide incident light passing through the device such that most of the light is dispersed away from specific areas of the device, such as intervening portions between the fluidic channels. By decreasing the amount of light incident upon these intervening portions, the amount of noise in the detection signal can be decreased when using certain optical detection systems. | ||||||
| 10 | Structures for controlling light interaction with microfluidic devices | US14316069 | 2014-06-26 | US09770715B2 | 2017-09-26 | David Steinmiller; Vincent Linder |
| Systems and methods for improved measurement of absorbance/transmission through fluidic systems are described. Specifically, in one set of embodiments, optical elements are fabricated on one side of a transparent fluidic device opposite a series of fluidic channels. The optical elements may guide incident light passing through the device such that most of the light is dispersed away from specific areas of the device, such as intervening portions between the fluidic channels. By decreasing the amount of light incident upon these intervening portions, the amount of noise in the detection signal can be decreased when using certain optical detection systems. | ||||||
| 11 | Urinary biomarker for use in test for prostate cancer | US14389320 | 2013-03-28 | US09575053B2 | 2017-02-21 | Kenji Nakayama; Kazuharu Shimizu; Jun Utsumi; Takahiro Inoue; Osamu Ogawa |
| A novel method that enables prostate cancer testing that is noninvasive and more accurate than conventional methods is disclosed. The present inventors intensively analyzed urine samples from prostate cancer patients, and non-cancer subjects, who are free of prostate cancer, and, as a result, newly discovered urinary peptides that can be used as indicators in prostate cancer testing. Use of these urinary peptides as indicators enables various prostate cancer-related tests including detection of prostate cancer, discrimination between prostate cancer and benign prostatic hyperplasia, monitoring of a therapeutic effect of prostate cancer therapy and monitoring of postoperative recurrence. | ||||||
| 12 | Vectors for expression of prostate-associated antigens | US14527226 | 2014-10-29 | US09402901B2 | 2016-08-02 | Joseph John Binder |
| The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers. | ||||||
| 13 | Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same | US14552030 | 2014-11-24 | US09399056B2 | 2016-07-26 | David B. Weiner; Jian Yan; Bernadette Ferraro; Niranjan Y. Sardesai; Mathura P. Ramanathan |
| Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | ||||||
| 14 | Compositions and methods comprising KLK3 of FOLH1 antigen | US11798177 | 2007-05-10 | US09012141B2 | 2015-04-21 | Yvonne Paterson; John Rothman; Vafa Shahabi |
| The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same. | ||||||
| 15 | CONSENSUS PROSTATE ANTIGENS, NUCLEIC ACID MOLECULE ENCODING THE SAME AND VACCINE AND USES COMPRISING THE SAME | US13883978 | 2011-11-14 | US20130302361A1 | 2013-11-14 | David B. Weiner; Jian Yan; Bernadette Ferraro; Niranjan Y Sardesai; Marthura P. Ramanathan |
| Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | ||||||
| 16 | Forms of prostate specific antigens and methods for their detection | US09792692 | 2001-02-23 | US20020058291A1 | 2002-05-16 | Stephen D. Mikolajczyk; Harry G. Rittenhouse; Abhay Kumar; Mohammad S. Saedi; Robert L. Wolfert |
| Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer. | ||||||
| 17 | 前立腺癌処置のための組成物およびワクチン | JP2018128767 | 2018-07-06 | JP2018184422A | 2018-11-22 | カレン,カール−ヨーセフ; フォティン−ムレシェック,マリオラ; グナート−フォークト,ウルリーケ; ランダー,トーマス |
| 【課題】効果的に免疫システムを刺激して、DNAベースの組成物に起因する導入遺伝子の非制御増殖の問題を避けつつ、前立腺癌(PCa)の処置を可能にするための、RNAベースの新規抗原組成物の提供。 【解決手段】少なくとも1つのmRNAを含む組成物であって、上記少なくとも1つのmRNAは、以下の抗原:STEAP(前立腺の6回膜貫通型上皮抗原);PSA(前立腺特異抗原);PSMA(前立腺特異膜抗原);PSCA(前立腺幹細胞抗原);PAP(前立腺酸フォスファターゼ);及びMUC1(ムチン1)、又はこれらのフラグメントをコードしており、かつ、上記少なくとも1つのmRNAは、モノシストロニック、バイシストロニック又はマルチシストロニックである、組成物。前記組成物を含有するワクチン。 【選択図】なし |
||||||
| 18 | 自動分析装置、分析システム及び自動分析装置の動作方法 | JP2016520811 | 2014-05-19 | JP6323816B2 | 2018-05-16 | 濱田 和幸; 秋場 猛; 大山 力; 米山 徹; 飛澤 悠葵; 竹内 俊文 |
| 19 | 前立腺関連抗原を発現させるためのベクター | JP2016526872 | 2014-10-17 | JP2016535989A | 2016-11-24 | ジョン ビンダー ジョセフ; キム チョー ヘレン |
| 本開示は、(a)2種、3種、またはそれより多くの免疫原性PAAポリペプチドをコードする多抗原構築物を含むベクター、(b)それらのベクターを含む組成物、(c)免疫応答を誘発するため、または前立腺癌を治療するために、それらのベクターおよび組成物を使用することに関する方法を提供する。【図1】 | ||||||
| 20 | Compositions and methods comprising klk3, psca, or folh1 antigen | JP2013219162 | 2013-10-22 | JP2014064569A | 2014-04-17 | YVONNE PATERSON; JOHN ROTHMAN; VAFA SHAHABI |
| PROBLEM TO BE SOLVED: To provide strains useful for enhancing immunogenicity of prostate specific antigen (PSA), which is a marker for prostate cancer, especially antigens useful in prevention and treatment of tumors and intracellular pathogens.SOLUTION: The present invention provides KLK3 peptides, recombinant polypeptides comprising the same, recombinant nucleotide molecules encoding the same, and recombinant Listeria strains comprising the same. The strains can be utilized for immunogenic methods and therapeutic methods. The sequence of a KLK3 peptide is selected from a specific group of sequences. Alternatively, the KLK3 peptide is an immunogenic KLK3 peptide, or any other KLK3 peptide. | ||||||
QQ群二维码
意见反馈
意见反馈